Although the therapeutic potential of MetAP2 inhibitors in T2DM and obesity has been recognized, direct links between MetAP2 inhibition and the modulation of these myristoylated proteins remain unproven. This evidence concerns the gene METAP2 and obesity due to melanocortin 4 receptor deficiency.